EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

Stage 4: How should you compare GLP-1 pharmacy quotes?

Dose Diligence research deskSection 12 · Page 5 of 11Last updated 17 Nov 2026

Compare matched scenarios and keep three financial ledgers: clinic costs, patient outlay and insurer payments. Do not describe a lower patient cash price as a clinic saving unless the clinic actually bears that expenditure.

Quote-comparability checklist

Require every candidate to specify:

  • Exact medicine, presentation, strength, quantity and supply period.
  • Clinician-provided dose-mix assumptions—not a supplier-generated treatment schedule.
  • Introductory and ongoing prices, eligibility conditions and quotation expiry.
  • Dispensing, shipping, supplies, platform, implementation and integration charges.
  • Failed-delivery, replacement, refund and cancellation treatment.
  • Minimum commitments, deposits, credit terms and price-change rights.
  • Applicable storage, expiry and in-use limits affecting wastage.
  • Who pays each charge and which charges are negotiable.

Published access terms illustrate why these fields matter: NovoCare distinguishes introductory offers from subsequent pricing and defines some supplies as a box of four pens while tablet supplies use 30-tablet bottles. Capture the applicable terms for your exact scenario instead of comparing the word “month.” (novocare.com)

Illustration—not a market price: $400 per 28-day supply means $5,200 for thirteen supplies covering 364 days. Modelling twelve payments would produce $4,800 and cover only 336 days.

For any proposed compounded multi-dose-vial scenario that passes the route screen, obtain clinical/pharmacy review of usable supply and wastage assumptions. FDA currently recommends discarding these vials within 28 days after first use, even when medication remains; do not value leftover contents as usable inventory without resolving the applicable guidance. (fda.gov)

Which cost and performance measures should the workbook show?

Use the following proposed management definitions, agreed before comparing candidates:

MeasureDefinition
Clinic cost per enrolled patient-monthAll attributable clinic-paid access costs for the cohort and period ÷ enrolled patient-months
Clinic cost per successfully fulfilled patient-monthThe same clinic-cost numerator, including failed-order costs, ÷ patient-months meeting the agreed fulfilment standard
Fulfilment success ratePatient-months meeting the standard ÷ patient-months expected to require supply, with documented clinical holds reported separately
Patient affordabilityPatient-paid medicine and mandatory access charges, net of applicable refunds or credits, shown separately from clinic costs
Implementation exposureOne-time implementation, overlap, exit and non-refundable commitment costs

Define successful fulfilment as all expected supply for that patient-month arriving within the agreed window without an unresolved product-quality exception. It measures access—not adherence, clinical effectiveness or treatment success.

Lock the cohort and expected supply requirements in advance. Report rejected prescriptions, unpaid orders, cancellations and clinical holds separately so that changes in the denominator remain visible.

Run at least three scenarios: expected operations, lower-than-planned volume and a disruption requiring replacement or migration. Avoid changing medicines or doses merely to make prices look comparable; those are clinical decisions.

Exit test: finance can reconcile every figure to a quotation, actual operating data or a labelled assumption, and identify the party that receives each potential saving.

Explore the table row by row

A working view of the research

Clinic cost per enrolled patient-month

Definition
All attributable clinic-paid access costs for the cohort and period ÷ enrolled patient-months

Sources cited on this page

  1. novocare.com · Source 1 ↗https://www.novocare.com/hcp/delivery.html
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Section sources →